PHARMA INVEST

Active

Public limited companyfounded 1993active for 33 yearsWaterloosesteenweg 799, 1180 Ukkel, BelgiumKBO/BCE: BE 0449.788.505

Summary

PHARMA INVEST has been active since 1993 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €726,362 and a net result of €22,151. Equity is growing by about 7% per year across the filed financial years. The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow Report Compare

PHARMA INVESTActiveChecked score 96/100

Risk analysis Report Compare

Activity

Activity not known1 site

Size

≈ €150,000turnover 2025, estimated

Equity: €726,362
Profit: €22,151

Turnover estimated from the gross margin

Financial health

96 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: < 0.1%

Structure

Parent: SOPHAGEM · 100%

Béatrice MorettiManaging director
SOPHAGEMManaging director · permanent representative Béatrice Moretti

2025 accounts filed 24 days late1 of 5 deeds summarised

Why 96raises riskProfit of €22,151 (financial year 2025)lowers riskSize: total assets €822,626Equity €726,362 (88.3% of total assets)Liquidity: current ratio 3.68, cash €180,559Show the evidence

Checked score

Score 2025

96 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 65% of its sector peers (no NACE code, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Strong

Solvency 100=

equity 88.3% of total assets

Liquidity 77+8

short-term debt 11.4% · cash 21.9%

Profitability 72-7

return on assets 2.7%

Bankruptcy probability, 12 months

< 0.1% Very low

0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 11-2024: 0.1% 12-2024: 0.1%● unchanged vs 11-2024 01-2025: 0.1%● unchanged vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.1%● unchanged vs 04-2025 06-2025: 0.1%● unchanged vs 05-2025 07-2025: 0.1%● unchanged vs 06-2025 08-2025: 0.2%▲ +0.1 percentage points vs 07-2025highest value 09-2025: < 0.1%▼ -0.2 percentage points vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025lowest value 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: 0.1%▲ +0.1 percentage points vs 07-2026 09-2026: < 0.1%▼ -0.1 percentage points vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026

Credit of up to €65,000 on 30-day terms is acceptable

Liquidity ample (current ratio 3.68, compared with 3.89 in 2024, above the usual 1.5; short-term debt: 11.4% and cash: 21.9% of total assets), and 11.7% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro): better than 81% on solvency, 71% on liquidity, 53% on profitability and 57% on growth.

The bankruptcy probability was computed on 28-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskraises risk

Size: total assets €822,626

Companies of this size fail less often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Equity €726,362 (88.3% of total assets)

NBB · annual accounts

Liquidity: current ratio 3.68, cash €180,559

NBB · annual accounts

Profit of €22,151 (financial year 2025)

NBB · annual accounts

2025 accounts filed 24 days late

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 24-08-2026, 24 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.

NBB · 10 filings

Deviation from the deadline

2025

24 days late

2024

1 day early

2023

30 days late

2022

32 days early

2021

18 days early

2020

30 days late

2019

39 days early

← before the deadline after the deadline →

tick = median of all Belgian filings

This company filed its last 7 accounts on average 1 day before the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 30 July (4 of the last 5 filed years within 31 days of that day).

Companies Code · seven months

Where today falls in the filing period

29-10-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

24-08-2026 Annual accounts filedfinancial year 2025 · full…
07-10-2025 Reappointments: SOPHAGEM srl (director and managing…Permanent representative: Béatrice Moretti
30-07-2025 Annual accounts filedfinancial year 2024 · full…

Key points

Positive: 8 profitable years in a rowprofit 2025: €22,151 8 years View
Controlled by SOPHAGEM 100% View
Active since 1993founded 31-03-1993 33 years View

By topic

Financials

Financial year: 2025
Total assets: €822,626
Profit: €22,151
Solvency: 88.3%

Total assets▲ 5.6%

Net result

20182025

Go to Financials

Board & ownership

Board: 2 members
Parent: SOPHAGEM · 100%

Béatrice MorettiManaging director
SOPHAGEMManaging director

Go to Board & ownership

Timeline

Events: 38
Since: 1994
Next accounts: by 31-07-2027

31-12-2024Highest result from 2018 to 2025
30-08-2024Annual accounts filed
31-12-2023Weakest financial year

Go to Timeline

Company details

Sites: 1

Legal form: Public limited company
Founded: 31-03-1993
Year ends: 31-12
Peppol: Not found in the Peppol directory

Go to Company details

Key facts about PHARMA INVEST

What is the company number of PHARMA INVEST?: 0449.788.505. In Belgium the VAT number is the company number with BE in front: BE 0449.788.505.
Where is PHARMA INVEST based?: The registered office is at Waterloosesteenweg 799, 1180 Ukkel.Company details
What is the legal form of PHARMA INVEST?: Public limited company (NV).
When was PHARMA INVEST founded?: On 31-03-1993.
Is PHARMA INVEST still active?: Yes, PHARMA INVEST is an active enterprise in the KBO register.
What is the turnover of PHARMA INVEST?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
Is PHARMA INVEST profitable?: In financial year 2025, PHARMA INVEST made a profit of €22,151.
Where can I find the annual accounts of PHARMA INVEST?: PHARMA INVEST filed 33 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PHARMA INVEST due?: By 31-07-2027, for financial year 2026.Timeline